Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.

Cancers (Basel) · 2020 · PMC7794906 · PMID 33375286

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

The study was negative in the primary efficacy analysis, with a median follow-up of 15.0 months; however, the combination arm showed a trend for longer survival compared to standard treatment (HR = 0.71; 95% CI, 0.50–1.02; p = 0.062).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.